# panRAFi_MEKi_combo

Repository for paper on precision targeting by panRAF and MEK inhibitors in melanoma.

The following list contains links to the scripts used to generate figures found in the paper along with the raw figures generated by those scripts:

* Figure 1
  *  1a-1c [[script - Drug_screen_analysis.R](scripts/Drug_screen_analysis.R)]
  *  1a [[figure - sa_metrics_heatmaps_RV.pdf](figures/Drug_screen/sa_metrics_heatmaps_RV.pdf)]
  *  1b [[figure - combo_metrics_heatmap_RV.pdf](figures/Drug_screen/combo_metrics_heatmap_RV.pdf)]
  *  1c [[figure - combo_bliss_heatmap_RV.pdf](figures/Drug_screen/combo_averaged_bliss_heatmap_GR.pdf)]
* Figure 2
  * 2e [[script - WB_dose_response.ipynb](scripts/model_simulation_and_plotting/WB_dose_response/WB_dose_response.ipynb)]
  * 2e [[figure - BRAF_V600E.svg](figures/Model_predicted_ss_dose_response_plots/BRAF_V600E.svg), [figure - NRAS_Q61_w_CRAF_Feedback.svg](figures/Model_predicted_ss_dose_response_plots/NRAS_Q61_w_CRAF_Feedback.svg)]
* Figure 3
  * 3a-3c [[script - bliss_heatmaps_Belva_Cobi_MARM2_BRAF_V600E.ipynb](scripts/model_simulation_and_plotting/Bliss_Heatmaps/bliss_heatmaps_Belva_Cobi_MARM2_BRAF_V600E.ipynb),[script - bliss_heatmaps_Belva_Cobi_NRAS_Q61_CRAF_optional.ipynb](scripts/model_simulation_and_plotting/Bliss_Heatmaps/bliss_heatmaps_Belva_Cobi_NRAS_Q61_CRAF_optional.ipynb)]
  * 3a,3c [[figure - Scaled_Belva_Cobi_SS_BRAF_V600E.svg](figures/Model_predicted_synergy/Scaled_Belva_Cobi_SS_BRAF_V600E.svg)]
  * 3b,3c [[figure - Scaled_Belva_Cobi_SS_NRAS_Q61_w_CRAF_feedback.svg](figures/Model_predicted_synergy/Scaled_Belva_Cobi_SS_NRAS_Q61_w_CRAF_feedback.svg)]
  * 3c [[figure - A375_IF.png](figures/Experimental_dose_response/A375_IF.png), [figure - IPC298_IF.png](figures/Experimental_dose_response/IPC298_IF.png)]
* Figure 4
  * 4a,4b [[script - Dose_projection_invitro.R](scripts/Dose_projection_invitro.R)]
  * 4a,4b [[figure - Heatmaps_Blank_GR_FBS_10.pdf](figures/Dose_projections/Heatmaps_Blank_GR_FBS_10.pdf),[figure - DDose.pdf](figures/Dose_projections/DDose.pdf),[figure - Heatmaps_DA_all_doses_in_one_GR_FBS_10.pdf](figures/Dose_projections/Heatmaps_DA_all_doses_in_one_GR_FBS_10.pdf),[figure - Dose_Projection_Heatmaps_GR_FBS_10.pdf](figures/Dose_projections/Dose_Projection_Heatmaps_GR_FBS_10.pdf)]
* Figure 5
  * 5a,5b [[script - Invivo_predictions.R](scripts/Invivo_predictions.R)]
  * 5a [[figure - Heatmaps_DA_all_doses_in_one_GR_FBS_10.pdf](figures/Invivo_predictions/Heatmaps_DA_all_doses_in_one_GR_FBS_10.pdf),[figure - Heatmaps_DA_all_doses_in_one_RV_FBS_10.pdf](figures/Invivo_predictions/Heatmaps_DA_all_doses_in_one_RV_FBS_10.pdf)]
  * 5b [[figure - Sim_Time_Course_DA_GR_FBS_10.pdf](figures/Invivo_predictions/Sim_Time_Course_DA_GR_FBS_10.pdf)]
* Figure 6
  * 6a, 6b [[script - single_PK_trajectories.R](scripts/single_PK_trajectories.R)]
  * 6a [[figure - Single_PK_traj_projection_GR_2_FBS_10.pdf](figures/PK_variability/Single_PK_traj_projection_GR_2_FBS_10.pdf)]
  * 6b [[figure - Violin_Plot_GR_2_FBS_10.pdf](figures/PK_variability/Violin_Plot_GR_2_FBS_10.pdf), [figure - Violin_Plot_Bliss_Excess_GR_2_FBS_10.pdf](figures/PK_variability/Violin_Plot_Bliss_Excess_GR_2_FBS_10.pdf)]
* Figure 7
  * 7a,7b [[script - clinical_tgi_analysis.R](scripts/clinical_tgi_analysis.R)]
  * 7a,7b [[figure - figure_7_other.png](figures/clinical_tgi/figure_7_other.png)]
* Supp Figure 2
  * S2 [[script - Simulate_DD_Belva_Cobi_Traj_MARM2_BRAF_V600E.ipynb](scripts/model_simulation_and_plotting/Time_Course_Response/Simulate_DD_Belva_Cobi_Traj_MARM2_BRAF_V600E.ipynb),[script - Simulate_DD_Belva_Cobi_Traj_NRAS_Q61_no_CRAF_feedback.ipynb](scripts/model_simulation_and_plotting/Time_Course_Response/Simulate_DD_Belva_Cobi_Traj_NRAS_Q61_no_CRAF_feedback.ipynb),[script - Simulate_DD_Belva_Cobi_Traj_NRAS_Q61_with_CRAF_feedback.ipynb](scripts/model_simulation_and_plotting/Time_Course_Response/Simulate_DD_Belva_Cobi_Traj_NRAS_Q61_with_CRAF_feedback.ipynb),[script - WB_dose_response.ipynb](scripts/model_simulation_and_plotting/WB_dose_response/WB_dose_response.ipynb)]
  * S2 [[figure - BRAF_V600E_double_dose.svg](figures/Model_predicted_temporal_response/BRAF_V600E/BRAF_V600E_double_dose.svg),[figure - NRAS_Q61_no_CRAF_double_dose.svg](figures/Model_predicted_temporal_response/NRAS_Q61/NRAS_Q61_no_CRAF_double_dose.svg),[figure - NRAS_Q61_w_CRAF_double_dose.svg](figures/Model_predicted_temporal_response/NRAS_Q61/NRAS_Q61_w_CRAF_double_dose.svg),[figure - NRAS_Q61_no_CRAF_Feedback.svg](figures/Model_predicted_ss_dose_response_plots/NRAS_Q61_no_CRAF_Feedback.svg)]
* Supp Figure 3
  * S3 [[script - single_PK_trajectories.R](scripts/single_PK_trajectories.R)]
  * S3 [[figure - PK_trajectories.pdf](figures/PK_variability/PK_trajectories.pdf)]
  
